Novartis India Limited is involved in the pharmaceutical business in India. The company offers therapeutic products in the areas of bone and pain products under the Voveran brand; transplantation immunology products under the Simulect, Certican, Sandimmun, Neoral, and Myfortic brands. It also offers neuroscience products under the Tegrital and Exelon brands. Novartis India Limited was incorporated in 1947 and is headquartered in Mumbai, India. The company is a subsidiary of Novartis AG.
| Current Price | ₹1,464.85 |
|---|---|
| Market Cap | ₹3,617 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Products |
| P/E Ratio | 38.8 |
| Return on Equity | 11.63% |
| 52-Week Range | ₹672.25 – ₹1,589.20 |
| Beta (1Y) | -0.1 |
| Dividend Yield | 0.00% |
1. Pharmaceutical Business-100%
Novartis India Ltd. is trading at ₹1,464.85, with a market capitalisation of ₹3,617 Cr.
Novartis India Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Products).
Novartis India Ltd. has a P/E of 38.8 and a return on equity of 11.63%.